JP2026505092A - 注射用組成物、それを含む医薬製剤及びその製造方法 - Google Patents
注射用組成物、それを含む医薬製剤及びその製造方法Info
- Publication number
- JP2026505092A JP2026505092A JP2025544851A JP2025544851A JP2026505092A JP 2026505092 A JP2026505092 A JP 2026505092A JP 2025544851 A JP2025544851 A JP 2025544851A JP 2025544851 A JP2025544851 A JP 2025544851A JP 2026505092 A JP2026505092 A JP 2026505092A
- Authority
- JP
- Japan
- Prior art keywords
- injectable composition
- composition according
- albumin
- sbe
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2023-0013947 | 2023-02-01 | ||
| KR20230013947 | 2023-02-01 | ||
| PCT/IB2024/050869 WO2024161316A1 (en) | 2023-02-01 | 2024-01-31 | Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026505092A true JP2026505092A (ja) | 2026-02-10 |
| JP2026505092A5 JP2026505092A5 (https=) | 2026-04-30 |
Family
ID=92024104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025544851A Pending JP2026505092A (ja) | 2023-02-01 | 2024-01-31 | 注射用組成物、それを含む医薬製剤及びその製造方法 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4658244A1 (https=) |
| JP (1) | JP2026505092A (https=) |
| KR (1) | KR20240121186A (https=) |
| CN (1) | CN118415999A (https=) |
| AR (1) | AR131668A1 (https=) |
| AU (1) | AU2024215883A1 (https=) |
| CL (1) | CL2025002270A1 (https=) |
| CO (1) | CO2025011347A2 (https=) |
| DO (1) | DOP2025000185A (https=) |
| IL (1) | IL322431A (https=) |
| JO (1) | JOP20250189A1 (https=) |
| MX (1) | MX2025008735A (https=) |
| PE (1) | PE20252396A1 (https=) |
| TW (1) | TW202432120A (https=) |
| WO (1) | WO2024161316A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120827558A (zh) * | 2024-04-19 | 2025-10-24 | 丽珠医药集团股份有限公司 | 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1682133A1 (en) * | 2003-11-03 | 2006-07-26 | AstraZeneca AB | Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux |
| AR051041A1 (es) * | 2004-10-04 | 2006-12-13 | Altana Pharma Ag | Bencimidazoles triciclicos condensados |
| FI20086158A0 (fi) * | 2008-12-03 | 2008-12-03 | Mikael Dahlstroem | Imidatsopyridiinijohdannaiset |
| GB0906470D0 (en) * | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| KR101777971B1 (ko) * | 2016-07-05 | 2017-09-12 | 제일약품주식회사 | 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도 |
-
2023
- 2023-11-20 TW TW112144715A patent/TW202432120A/zh unknown
- 2023-11-29 CN CN202311609051.XA patent/CN118415999A/zh active Pending
-
2024
- 2024-01-23 AR ARP240100149A patent/AR131668A1/es unknown
- 2024-01-31 PE PE2025001666A patent/PE20252396A1/es unknown
- 2024-01-31 AU AU2024215883A patent/AU2024215883A1/en active Pending
- 2024-01-31 KR KR1020240014951A patent/KR20240121186A/ko active Pending
- 2024-01-31 IL IL322431A patent/IL322431A/en unknown
- 2024-01-31 EP EP24749813.2A patent/EP4658244A1/en active Pending
- 2024-01-31 WO PCT/IB2024/050869 patent/WO2024161316A1/en not_active Ceased
- 2024-01-31 JP JP2025544851A patent/JP2026505092A/ja active Pending
-
2025
- 2025-07-25 MX MX2025008735A patent/MX2025008735A/es unknown
- 2025-07-28 JO JOJO/P/2025/0189A patent/JOP20250189A1/ar unknown
- 2025-07-30 CL CL2025002270A patent/CL2025002270A1/es unknown
- 2025-07-31 DO DO2025000185A patent/DOP2025000185A/es unknown
- 2025-08-22 CO CONC2025/0011347A patent/CO2025011347A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR131668A1 (es) | 2025-04-16 |
| CO2025011347A2 (es) | 2025-09-18 |
| IL322431A (en) | 2025-09-01 |
| KR20240121186A (ko) | 2024-08-08 |
| AU2024215883A1 (en) | 2025-07-31 |
| CN118415999A (zh) | 2024-08-02 |
| MX2025008735A (es) | 2025-11-03 |
| DOP2025000185A (es) | 2026-02-15 |
| EP4658244A1 (en) | 2025-12-10 |
| CL2025002270A1 (es) | 2025-10-03 |
| TW202432120A (zh) | 2024-08-16 |
| JOP20250189A1 (ar) | 2025-07-28 |
| PE20252396A1 (es) | 2025-10-10 |
| WO2024161316A1 (en) | 2024-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2626236T3 (es) | Uso de polioles para obtener formas polimorfas estables de rifaximina | |
| RU2770366C2 (ru) | Препараты даптомицина | |
| CN110876259B (zh) | 注射用组合物 | |
| KR20040085196A (ko) | 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법 | |
| EP0649655A1 (en) | Injectable solutions containing anti-ulcer benzimidazoles and amides | |
| JP7374501B2 (ja) | メロキシカム組成物、製剤及びその製造方法と応用 | |
| JP2012167132A (ja) | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤 | |
| JP2006500367A (ja) | ブチルフタリドとシクロデキストリンまたはその誘導体との包接複合体、それらの調製のためのプロセスおよびその使用 | |
| JP2026505092A (ja) | 注射用組成物、それを含む医薬製剤及びその製造方法 | |
| CN103561723B (zh) | 具有改善稳定性的奥米沙班制剂 | |
| JPH0136445B2 (https=) | ||
| KR100725076B1 (ko) | Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물 함유 용액 및 제제 | |
| CN100376251C (zh) | 含有甲基维生素b12的冻干制剂及其制备方法 | |
| EA008145B1 (ru) | Инъецируемая галеновая форма флупиртина | |
| HK40111340A (zh) | 可注射组合物、包含其的药物制剂以及制备该组合物的方法 | |
| JPH0343251B2 (https=) | ||
| JP3956654B2 (ja) | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤 | |
| JP6862447B2 (ja) | ダニリキシンの静脈内注射用製剤 | |
| KR100973470B1 (ko) | 칼시토닌-폴리포스페이트의 복합체 및 그의 제조방법 | |
| RU2285696C2 (ru) | Комплексы включения бутилфталида с циклодекстрином или его производными, способ их получения и их применение | |
| KR100673558B1 (ko) | 사이클로덱스트린 또는 이의 유도체와 부틸프탈리드의 내포 착물, 이들의 제조 방법 및 용도 | |
| CN1589795A (zh) | 尼莫地平冻干组合物及其制备方法 | |
| JP2005200409A (ja) | 注射剤 | |
| HK40025124B (zh) | 注射用组合物 | |
| RU2025123844A (ru) | Инъекционная композиция, фармацевтический состав, содержащий ее, и способ получения композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260421 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260421 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20260421 |